Vascular smooth muscle contraction pathway

Vascular smooth muscle contraction pathways comprise a network of molecular mechanisms that regulate the contraction state of blood vessels. Contraction is primarily controlled by an increase in intracellular calcium, which binds to calmodulin and activates myosin light chain kinase (MLCK), resulting in phosphorylation of myosin light chains and actin-myosin cross-bridge formation[1][3][6][7]. Key cell surface receptors such as the angiotensin II receptor type 1 (AT1), endothelin-1 receptor, alpha-adrenergic receptors, and others, signal through G proteins (mainly Gq) to activate phospholipase C, leading to production of second messengers (IP3 and DAG) that increase calcium and activate protein kinase C[1][4][6]. Rho-kinase pathways also contribute by inhibiting myosin light chain phosphatase and promoting sustained contraction[4][6]. Cytoskeletal remodeling, including actin polymerization and the involvement of focal adhesions, modulates the transmission and maintenance of contractile force[2][6]. Abnormal activation or dysregulation of these pathways is implicated in cardiovascular diseases such as hypertension, arterial stiffness, and vascular remodeling[6][7]. Therapeutic interventions often target individual receptors or enzymes within these pathways rather than the entire system. Key point: "Vascular smooth muscle contraction pathways" are not a single molecule or receptor but a complex process involving numerous molecular targets; for structured therapeutic target information, specific pathway components should be identified and listed individually[1][3][4][6][7].

Other names

vascular contraction signalingvasoconstriction pathways

Blockade of calcium influx, reducing contraction (calcium channel blockers) - Blockade of vasoconstrictor G protein-coupled receptors, inhibiting downstream signaling (ARBs, endothelin antagonists) - Increased cAMP, inhibiting myosin light chain kinase (beta agonists) - Direct vasodilation by increasing cGMP (nitric oxide donors) - Inhibition of myosin light chain phosphorylation (Rho-kinase inhibitors, experimental)